Ciana Therapeutics is a clinical development-stage company lead by an experienced team. Their lead therapy is a small-molecule oral therapy that treats clinically validated pathologies of diabetic retinopathy (DR) and addresses a large unmet medical need. Unlike the leading injectable eye therapies that target VEGF to limit retinal edema, this novel oral therapy stabilizes cell-cell junctions, protects from retinal capillary breakdown and reduces vascular leakage and edema. By targeting the core disease pathology, this oral therapy is uniquely suited to address the need for more effective and less burdensome therapies for all DR patients
